NCT05166837 - The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

January 12, 2023

Study Completion Date

January 12, 2023

Conditions

Healthy

Interventions

DRUG

STSA-1002 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

DRUG

STSA-1002 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

DRUG

STSA-1002 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

DRUG

STSA-1002 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

DRUG

STSA-1002 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

Trial Locations (5)

102600

Peking university People's Hospital, Beijing

230601

The second hospital of Anhui medical university, Hefei

510799

The fifth affiliated hosipital of Guangzhou medical university, Guangzhou

518036

Peking university Shenzhen Hospital, Shenzhen

550004

The affiliated hospital of Guizhou medical university, Guiyang

All Listed Sponsors

lead

Staidson (Beijing) Biopharmaceuticals Co., Ltd

INDUSTRY